We claim:

Sub. 0/5

A modified anti-viral peptide comprising:

 a peptide that exhibits anti-viral activity, and
 a reactive group which is reactive with amino groups, hydroxyl groups, or

thiol groups on blood components to form stable covalent bonds.

2. The modified peptide of claim 1 wherein said reactive group is a succinimidal or a maleimido group.

10

3. The modified peptide of claim 1 wherein said reactive group is a maleimido group which is reactive with a thiol group on a blood protein.

4. The modified peptide of claim 1 wherein said peptide is DP178 or DP107 or analogs thereof.


5. The modified peptide of claim 1 wherein said peptide exhibits antiviral activity against human immunodeficiency virus (HIV).

20

6. The modified peptide of claim 5 wherein said peptide is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:9.

7. The modified peptide of claim 5 wherein said peptide is DP 178 or DP 107.

- 8. The modified peptide of claim 1 wherein said peptide exhibits antiviral activity against human respiratory syncytial virus (RSV).
- 9. The modified peptide of claim 8 wherein said peptide is selected from the group consisting of SEQ ID NO:10 to SEQ ID NO:30.



5

- 11. The modified peptide of claim 1 wherein said peptide exhibits antiviral activity against human parainfluenza virus (HPIV).
- 12. The modified peptide of claim 11 wherein said peptide is selected from the group consisting of SEQ ID NO:31 to SEQ ID NO:62.
 - 13. The modified peptide of claim 11 wherein said peptide is selected from the group consisting of SEQ ID NO: 35, SEQ ID NO:38 to SEQ ID NO:42, SEQ ID NO:52 and SEQ ID NO:58.

15

20

- 14. The modified peptide of claim 1 wherein said peptide exhibits antiviral activity against measles virus (MeV).
- 15. The modified peptide of claim 14 wherein said peptide is selected from the group consisting of SEQ ID NO:74 to SEQ ID NO:86.
 - 16. The modified peptide of claim 14 wherein said peptide is selected from the group consisting of SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81 and SEQ ID NO:84.

- 17. The modified peptide of claim 1 wherein said peptide exhibits antiviral activity against simian immunodeficiency virus (SIV).
- 18. The modified peptide of <u>claim 17</u> wherein said peptide is selected from the group consisting of SEQ ID NO:63 to SEQ ID NO:73.

10

5

15

20

25

- 19. A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising a peptide that exhibits anti-viral activity against human immunodeficiency virus (HIV), modified with a reactive group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.
- 20. The composition of claim 19 wherein said reactive group is a maleimido group which is reactive with a thiol group on a blood protein.
- 21. The composition of claim 20 wherein said peptide is DP178 or DP107 or analogs thereof
- 22. A composition for use in the prevention and/or treatment of human respiratory syncytial virus (RSV) infection comprising a peptide that exhibits antiviral activity against RSV, modified with a reactive group which is reactive with amino groups, hydroxyl groups, or thiol/groups on blood components to form stable covalent bonds.
- 23. The composition of claim 22 wherein said reactive group is a maleimido group which is reactive with a thiol group on a blood protein.
- 24. The composition of claim 23 wherein said peptide is selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:17 and SEQ ID NO:29.
- A/composition for use in the prevention and/or treatment of human parainfluenza virus (HPIV) infection comprising a peptide that exhibits anti-viral activity against human parainfluenza (HPIV), modified with a reactive group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.

- 26. The composition of claim 25 wherein said reactive group is a maleimido group which is reactive with a thio group on a blood protein.
- 5 27. The composition of claim 2/6 wherein said peptide is selected from the group consisting of SEQ ID NO: 35, SEQ ID NO:38 to SEQ ID NO:42, SEQ ID NO:52 and SEQ ID NO:58.
 - A composition for use in the prevention and/or treatment of measles 28. virus (MeV) infection comprising/a peptide that exhibits anti-viral activity against measles virus (MeV), modified with a reactive group which is reactive with amino groups, hydroxyl groups, or theol groups on blood components to form stable covalent bonds.
 - The composition of claim 28 wherein said reactive group is a 29. maleimido group which/is reactive with a thiol group on a blood protein.
 - 30. The composition of claim 29 wherein said peptide is selected from the group consisting of SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81 and SEQ ID NO:84.

adda8

10

15